Core Viewpoint - The Hong Kong Stock Connect innovative drug sector is experiencing significant capital inflow, indicating a potential favorable timing for investment in this sector as the innovative drug ETF (520880) shows strong performance despite recent declines [1][3][8]. Group 1: Market Performance - On January 19, the Hong Kong Stock Connect innovative drug ETF (520880) fell by 2.72%, marking three consecutive days of decline, yet recorded a net subscription of 85.51 million yuan, the highest single-day inflow in nearly a month [1][8]. - The latest fund size of the innovative drug ETF reached 2.296 billion yuan, maintaining a historical high with a total of 4.25 billion shares [4][11]. Group 2: Investment Opportunities - Short-term prospects for leading pharmaceutical companies are promising, with 2025 earnings forecasts potentially exceeding expectations, which could lead to valuation recovery opportunities [3][10]. - The first quarter is typically a peak period for overseas licensing transactions, making innovative drug companies with pipeline value, such as those with ADC, bispecific antibodies, and small RNA platforms, worthy of attention [3][10]. Group 3: Long-term Sector Logic - The core logic of the Hong Kong Stock Connect innovative drug sector remains robust, with expected overseas licensing totals for innovative drugs reaching 135.7 billion USD in 2025, reflecting global recognition of Chinese pharmaceutical R&D capabilities [3][10]. - Continued policy support is anticipated, with the National Medical Products Administration (NMPA) expected to approve 76 innovative drugs in 2025, the highest globally, and ongoing optimization of the drug review and approval process [3][10]. Group 4: ETF Characteristics - The innovative drug ETF (520880) exclusively invests in innovative drug R&D companies, with over 73% of the top ten holdings representing leading firms in the sector, indicating a strong core strength [5][12][14]. - The ETF is designed to manage risks effectively by reducing the weight of less liquid component stocks, thereby controlling tail risks [6][13].

Core Viewpoint - The Hong Kong stock market experienced an overall pullback, but the innovative drug sector saw significant gains, with BeiGene rising over 7% to reach a three-year high, and the Hong Kong Stock Connect Innovative Drug ETF (520880) continuing to rise by 3% despite the market downturn [1] Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) saw its fund size exceed 2 billion yuan for the first time on November 3, marking a 392% increase since its launch on July 7 [1] - The innovative drug index has historically experienced an average pullback duration of 30-40 days, with a typical decline of around 20% [1] - The current adjustment has lasted nearly a quarter, with the index down over 20%, indicating a potential high-probability entry point for investors [1] Group 2: Industry Trends - The trend of Chinese innovative drugs going global is clear, supported by ongoing drug review reforms and favorable policies [1] - The Chinese innovative drug industry has entered its 2.0 era, shifting from "importing and imitating" to "innovating and exporting" [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked fund (025221) track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively invests in innovative drug R&D companies, with over 70% of its holdings in large-cap innovative drug leaders [2]

Group 1 - The Hong Kong innovative drug sector is experiencing a rebound after a two-month pullback, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising over 3% and quickly surpassing the 20-day moving average [1] - Significant capital has been flowing into the Hong Kong innovative drug sector, with the fund size of the Hong Kong Stock Connect Innovative Drug ETF (520880) exceeding 2 billion yuan for the first time on November 3, marking a 392% increase since its launch on July 7 [1] - The fund manager of the Hong Kong Stock Connect Innovative Drug ETF (520880) indicated that the innovative drug market may be on the verge of a rally, suggesting that the current period may be a high-probability zone for investment [1] Group 2 - Huafu Securities believes that the focus of the innovative drug market is shifting from broad valuation recovery to the ability of companies to deliver on their fundamentals, with companies that have excellent clinical data, strong commercialization capabilities, and successful international expansion potential likely to emerge as future winners [2] - The Hong Kong Stock Connect Innovative Drug ETF (520880) and its linked fund (025221) passively track the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which exclusively invests in innovative drug R&D companies, with over 70% of its holdings in large-cap innovative drug leaders [2] - As of the end of September, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has shown a year-to-date increase of 108.14%, outperforming other innovative drug indices [2]